, Directive 2001/83/CE du Parlement européen et du Conseil du 6 novemvre 2001 instituant un code communautaire relatif aux médicaments à usage humain. JO L 311 du 28 novembre, p.67, 2001.
, établissant des procédures communautaires pour l'autorisation et la surveillance des médicaments à usage humain et à usage vétérinaire et instituant une agence européenne pour l'évaluation des médicaments, 1993.
Guideline on similar biological medicinal products, vol.23 ,
, mars 2004 modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain. JO L 136 du 30 avril, 2004.
Opothérapie : émergence et développement d'une technique thérapeutique (France, 1889-1940) ,
Ecole doctorale Abbé Grégoire, 2014. ,
Histoire des vaccinations, John Libbey Eurotext, vol.474, 2008. ,
, ADSP, vol.23, issue.27, p.24, 1999.
, Fédération Française des diabétiques. Les 90 ans de la découverte de l'insuline
Les biosimilaires en 10 questions ,
,
Les biosimilaires en 15 questions, p.23, 2014. ,
,
, , 2006.
Biopharmaceutical benchmarks, Nat Biotechnol, vol.36, issue.12, pp.1136-1145, 2018. ,
,
,
, ANSM. Les médicaments biosimilaires
,
Public statement lusduna withdrawal marketing authorisation european union, 2018. ,
,
Actualités sur les biosimilaires, vol.12 ,
Biosimilar medicines: a cost-effective move towards patient access, 2018. ,
,
Etat des lieux sur les médicaments biosimilaires ,
Médicaments biosimilaires -Point d'information ,
,
L'essentiel sur les anticorps thérapeutiques, 2015. ,
,
Les médicaments biosimilaires dans l'UE Guide d'information destiné aux professionnels de la santé, p.24, 2017. ,
De la structure primaire à la structure quaternaire ,
,
, , 2009.
,
Les protéines recombinantes, 2015. ,
Les modifications post-traductionnelles. Grenoble, 2011. ,
Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review, BioDrugs. févr, vol.32, issue.1, pp.27-52, 2018. ,
« Les médicaments biosimilaires ? ? à vos marques, prêts, prescrivez ! ,
, Janvier, vol.22, p.742, 2018.
Les protéines recombinantes : historiques, perspectives, contrôle et réglementation. Grenoble, 2014. ,
Culture cellulaire : Trois étapes clés pour produire des protéines thérapeutiques. 1 avr, 2011. ,
,
Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, vol.17, 1999. ,
Comparability and biosimilarity: considerations for the healthcare provider, Curr Med Res Opin, vol.28, issue.6, pp.1053-1061, 2012. ,
International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Brouder A, Tietje C, éditeurs. Handbook of Transnational Economic Governance Regimes, pp.1041-54, 2009. ,
Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process, 2017. ,
,
Similarité des médicaments issus des biotechnologies : cadre réglementaire et spécificité, Ann Pharm Fr. août, vol.66, issue.4, pp.206-217, 2008. ,
Marketing Authorization of the Biosimilars, 2017. ,
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis. févr, vol.72, issue.2, pp.165-78, 2013. ,
The challenging definition of naïve patient for biological drug use, Autoimmun Rev. juin, vol.14, issue.6, pp.543-549, 2015. ,
Biosimilars: State of Clinical and Regulatory Science, J Pharm Pharm Sci. 12 sept, vol.20, issue.1, p.332, 2017. ,
Europe : les brevets contre l'accès aux médicaments, Prescrire. Mai, vol.29, issue.307, p.375, 2009. ,
Les brevets pharmaceutiques et l'Accord sur les ADPIC ,
,
,
,
,
6577 -115th Congress, PRICED Act, 2017. ,
, USC 262: Regulation of biological products
,
Medicinal Products Working Party, 2018. ,
Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW. Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics, 2009. ,
Biosimilars approved in Japan, 2018. ,
,
Japanese regulation of biosimilar products: past experience and current challenges: Japanese regulation of biosimilar products, Br J Clin Pharmacol. juill, vol.82, issue.1, pp.30-40, 2016. ,
Current Market and Regulatory Landscape of Biosimilars, Am J Manag Care, vol.24, issue.21, pp.451-456, 2018. ,
The US Biosimilar Market: Stunted Growth and Possible Reforms, Clin Pharmacol Ther. janv, vol.105, issue.1, pp.92-100, 2019. ,
Ce qu'il faut savoir sur les médicaments biosimilaires, 2013. ,
The Regulation of Biosimilars in Latin America, Curr Rheumatol Rep, vol.18, issue.3, 2016. ,
, Evaluate Pharma. World Preview, 2018.
,
Biosimilars: Global Markets. BCC Research, 2018. ,
,
, Embracing the Patent Cliff, Evaluate Pharma. World Preview, 2012.
,
The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Front Pharmacol, vol.8, 2017. ,
Company Strategies to Capture Value from the Biologics Market, Pharmaceuticals. 12 déc, vol.5, issue.12, pp.1393-408, 2012. ,
Biosimilars approved in Europe, 2018. ,
Biosimilar medicines, Mai, 2015. ,
Automatic pharmacist substitution of biosimilars in Germany, 2019. ,
Pharmacy-mediated substitution of biosimilars -a global survey benchmarking country substitution policies, GaBI Journal, vol.6, issue.4, pp.157-64, 2017. ,
, Memo Positioning statements on Physician-led switching for biosimilar medicines, 2019.
Biosimilar and Interchangeable Products: The U.S. FDA Perspective, p.21 ,
,
, The PHS Act. Sect, vol.351, issue.i
, The PHS Act. Sect, vol.351, issue.4
, Biosimilar medicines Information for pharmacists, Mai 2019
,
Who chooses whether the biosimilar medicine or the reference biological medicine is used?, 2019. ,
The Economic Implications of Biosimilars, vol.21, p.10, 2015. ,
, IMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Mediciness : the Role of Functioning Competitive Markets, 2016.
,
, Direction des Affaires Economiques du LEEM. Bilan économique 2018 des Entreprises du médicament
IQVIA. The impact of biosimilar competition in Europe, vol.40, 2018. ,
The impact of biosimilar competition in Europe, vol.33, 2017. ,
Is there a reason for concern or is it just hype? -A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars, Expert Opin Biol Ther. 3 août, vol.17, issue.8, pp.915-941, 2017. ,
Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme, J Crohns Colitis, vol.7, 2017. ,
Biosimilaires : de la technique au médicoéconomique, Therapies. janv, vol.70, issue.1, pp.37-46, 2015. ,
Le premier médicament au monde face au défi de la concurrence ,
, , 2018.
Biosimilars: A Multidisciplinary Perspective, Clin Ther. mai, vol.38, issue.5, pp.1238-1287, 2016. ,
Remboursabilité des spécialités biosimilaires et Convention sur "la relance des médicaments biosimilaires en Belgique ,
, , 2018.
Accord national médico-mutualiste, 2018. ,
, , 2017.
,
, INAMI. Médicaments biosimilaires : un incitant pour la prescription de médicaments biosimilaires en-dehors de l'hôpital, Février, p.82, 2019.
,
Biosimilars: How Can Payers Get Long-Term Savings?, PharmacoEconomics. juin, vol.34, issue.6, pp.609-625, 2016. ,
Policies for biosimilar uptake in Europe: An overview, PLoS ONE. Décembre, vol.12, issue.12, p.190147, 2017. ,
Factors Supporting a Sustainable European Biosimilar Medicines Market ,
, Septembre, 2014.
Factors influencing the economics of biosimilars in the US, J Med Econ. 2 déc, vol.20, issue.12, pp.1268-71, 2017. ,
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician, Curr Rheumatol Rep, vol.19, issue.6, 2017. ,
Guideline on good pharmacovigilance practices (GVP) Product-or Population-Specific Considerations II: Biological medicinal products, 2016. ,
Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products, 2014. ,
Biosimilar switching and related medical liability, J Forensic Leg Med. avr, vol.55, pp.93-97, 2018. ,
Protecting Access to Care Act of, 1215. ,
Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective, Ther Adv Gastroenterol, vol.12, p.175628481984274, 2019. ,
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet, vol.389, pp.2304-2320, 2017. ,
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry ,
,
Médicaments faisant l'objet d'un plan de gestion des risques (PGR) ,
,
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies, Int J Clin Pharm. Août, vol.40, issue.4, pp.778-82, 2018. ,
Post-authorisation safety studies (PASS) ,
,
Biosimilar switching -current state of knowledge, Reumatologia/Rheumatology, vol.56, issue.4, pp.234-276, 2018. ,
Biologicals and biosimilars: safety issues in Europe, Expert Opin Biol Ther. 3 juillet, vol.17, issue.7, pp.871-878, 2017. ,
Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases, Drug Saf. Août, vol.36, issue.8, pp.617-642, 2013. ,
, Qu'est-ce que le Dossier Pharmaceutique ?, 2019.
WHO says more communication and education needed to increase access to biosimilars, Mai 2019 ,
Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review, J Manag Care Spec Pharm. janv, vol.25, issue.1, pp.102-114, 2019. ,
AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries, Ann Rheum Dis. juin, vol.75, issue.2, pp.1008-1009, 2016. ,
Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey, On behalf of the CRI (Club "Rhumatismes et Inflammations"), vol.30, pp.585-92, 2016. ,
Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey, BMJ Open. juin, vol.7, issue.6, p.16730, 2017. ,
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey, J Crohns Colitis, vol.10, issue.11, pp.1362-1367, 2016. ,
Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland, Regul Toxicol Pharmacol. août, vol.88, pp.252-61, 2017. ,
Management between similar biological medicines, 2018. ,
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther. déc, vol.4, issue.2, pp.209-227, 2017. ,
Que dois-je savoir sur les médicaments biosimilaires -Information pour les patients, 2016. ,
Improving understanding of biosimilars in the EU, 2018. ,
, , 2018.
ACTION PLAN: Balancing Innovation and Competition, Juillet, 2018. ,
, Een praktische handleiding voor succesvolle implementatie van biosimilars in de medisch specialistische zorg, 2017.
, , 2017.
,
En savoir plus sur les biosimilaires, 2017. ,